Etravirin v klinické praxi
| Title in English | Etravirine in clinical practice |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Klinická farmakologie a farmacie |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | etravirine; HIV; NNRTI; cART |
| Description | Since the mid-nineties of the last century, combination antiretroviral therapy has been the main treatment strategy for HIV. Reverse transcriptase inhibitors are among the traditionally used drug classes. Etravirine is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Due to the need to combine drugs from different classes, each newly approved medicinal product is an option for patients with resistance or intolerance to previous therapy. Etravirine is generally characterized by high efficacy, a low risk of side effects and a higher resistance barrier in comparison with first-generation NNRTIs. |